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To the Editor: Permanent neonatal diabetes mellitus
(PNDM) is mainly caused by activating mutations in the
KCNJ11 or ABCC8 genes, encoding respectively the Kir6.2
and sulfonylurea receptor (SUR)1 subunits of the KATP
channels in the pancreatic beta cells [1–3]. Developmental
delay, epilepsy and neonatal diabetes syndrome (DEND)
represents the most severe clinical form of PNDM [4].
Besides diabetes mellitus patients exhibit severe develop-
mental delay, hypotonia and therapy-resistant epilepsy. As
KCNJ11 and ABCC8 are expressed in neuronal tissue the
neurological features in DEND syndrome are postulated to
result from mutated KATP channels in the brain. Only a few
cases of DEND syndrome have been described. More
common is a milder clinical picture, without generalised
epilepsy and with less severe developmental delay, referred
to as intermediate DEND.
Since 2006 many patients with PNDM due to KCNJ11
and ABCC8 mutations have been completely transferred
from insulin to sulfonylurea drugs [5, 6]. However, in
DEND syndrome only cases of intermediate DEND were
sulfonylurea-responsive [7, 8]. Shimomura and colleagues
reported the first patient with severe DEND syndrome, due
to a KCNJ11 mutation, who did completely switch to
sulfonylurea drugs [4]. Here we report a case of DEND
syndrome due to a novel ABCC8 mutation and successful
transfer to sulfonylurea treatment.
A boy was born as second child of non-consanguineous
white parents following an uneventful pregnancy and spon-
taneous term delivery. His birthweight was low (2,700 g, −2
standard deviation score [SDS]). At 7 weeks of age he
presented with failure to thrive (weight 3,140 g, −3.8 SDS),
severe hyperglycaemia (blood glucose 42 mmol/l), glucosu-
ria, and ketoacidosis. Physical examination revealed severe
generalised hypotonia without dysmorphic features or other
abnormalities. Islet cell auto antibodies, serum insulin and C-
peptide were undetectable. Abdominal ultrasound examina-
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diabetes mellitus was concluded and continuous intravenous
insulin therapy was started followed by continuous subcuta-
neous insulin pump therapy. This resulted in good glycaemic
control without significant hypoglycaemia. At the age of
5m o n t h sH b A 1c was 7.2% and catch-up growth (weight −2
SDS) was observed.
On the tenth day of admission, at the age of 2 months,
he developed frequent subtle seizures unresponsive to
increasing doses of the anti-epileptic drug phenobarbital.
EEG examination showed a burst-suppression pattern
(abnormal for the age of 8.5 weeks) and epileptic
discharges later on. At the age of 3 months the seizures
progressed to infantile spasms and EEG examination
demonstrated a slowed high-voltage background pattern
with multifocal epileptic discharges consistent with
hypsarrhythmia and unresponsive to various antiepileptic
drugs (phenobarbital, nitrazepam, adrenocorticotropic
hormone and vigabatrin). At age 5 months the boy was
severely hypotonic, with no visual contact, no babbling,
hardly any facial expression and a psychomotor devel-
opmental age of 1 month. Magnetic resonance imaging
of the brain at that age demonstrated no structural
abnormalities but mild atrophy of frontal–temporal
regions. DEND syndrome was suspected and the boy
was tested for KATP channel defects. Genomic DNA
isolated from peripheral lymphocytes was analysed by
direct sequencing of all coding sequences as well as the
relevant intron/exon boundaries. The KCNJ11 sequence
was wild type. In exon 1 of the ABCC8 gene a monoallelic
missense mutation was present (c.145A>T) that changed
amino acid residue 49 from isoleucine to phenylalanine (p.
I49F). This nucleotide change was not previously reported
in any single-nucleotide polymorphism or mutation data-
base, was absent in 70 control alleles and also absent in
genomic DNA from both parents, indicating a de novo
mutation.
In an attempt to influence both glycaemic control and
neurological abnormalities, at the age of 5.5 months oral
glibenclamide therapy was started in a daily dose of 0.2 mg/kg
body mass in two doses followed by weekly increments of
0.2 mg/kg
−1day
−1. The insulin dose could gradually be
reduced and after 2 months, at a glibenclamide dose of
1.6 mg/kg, insulin therapy was stopped. Side effects of
glibenclamide treatment were not noticed, and there were no
episodes of hypoglycaemia. Gradually the daily glibenclamide
dose was tapered and at the age of 17 months he continued to
have excellent glycaemic control with 1.0 mg/kg (HbA1c
5.6%). No improvement was observed in seizure control
despite anti-epileptic drug treatment with high dose vigabatrin
and levetiracetam. At the age of 26 months his functional
psychomotor age was 3 months and he continued to have
infantile spasms with unchanged EEG hypsarrhythmia.
To our knowledge, this is the first report of a DEND
patient with an ABCC8 mutation who successfully transfers
to sulfonylurea therapy. Although functional studies were
not performed the mutation is likely to be the molecular
origin of the patient’s DEND syndrome, as it is a de novo
mutation in a child of unaffected parents and affects an
amino acid residue that shows evolutionary conservation
across species. Based on the topology suggested by Conti
and colleagues, amino acid residue 49 is located either in
the N-terminal extracellular region or in the first predicted
transmembrane domain [9]. The in silico prediction
programs SIFT and PolyPhen both predicted that substitu-
tion at position 49 from isoleucine to phenylalanine would
affect protein function. The excellent response to sulfonyl-
urea treatment provides further evidence for the pathoge-
nicity of the mutation.
Shimomura and colleagues reported the first patient
with severe DEND syndrome, due to a KCNJ11
mutation, who completely switched to sulfonylurea drugs
[4]. Their patient also showed neurological improvement
on a dose of 2.3 mg/kg, suggesting that such extremely
high doses might influence neurological symptoms. In
our case glucose values dropped to 3.5 mmol/l with a
sulfonylurea dose of 1.6 mg/kg and further increasing the
sulfonylurea dosage was thought to be contraindicated by
the risk of hypoglycaemia. As the main aim in the
treatment of DEND syndrome is to influence neurolog-
ical dysfunction, perhaps increasing sulfonylurea doses
should have been considered together with an additional
treatment to prevent hypoglycaemia. Furthermore it
could be speculated that rather than a drug that targets
both SUR1 and SUR2 isoforms, such as glibenclamide, a
SUR1-specific drug, such as gliclazide, might influence
neurological symptoms more effectively as only SUR1
isoforms are present in neuronal KATP channels. It is not
clear to what extent sulfonylurea drugs are hindered by
the blood–brain barrier. Administering sulfonylurea
drugs at a very young age, when the blood–brain barrier
is still immature, might lead to better brain penetration
than at later ages.
This case report emphasises the importance of early
genetic analysis in all cases of neonatal diabetes mellitus,
including the most severely affected patients with DEND
syndrome as in this group, sulfonylurea treatment may also
completely restore glucose homeostasis. The effect on
neurological features is a field of future research perhaps
aiming at improved blood–brain barrier penetrance of
sulfonylurea drugs and allowing higher doses by alterna-
tively handling hypoglycaemia.
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